NCT05840029

Brief Summary

Ovarian cancer is the seventh most common cancer and the fifth leading cause of death in women worldwide. About 70% of patients with epithelial ovarian cancer present with advanced disease which will require a combination of cytoreductive surgery and chemotherapy to give them their best chance of long term survival.The presence of macroscopic pleural disease-especially if undetected and unresected after primary debulking surgery-may alter treatment decision-making and markedly affect survival. Video-Assisted Thoracoscopic Surgery (VATS) allows surgeons, through a minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor. Few studies reported that VATS altered the therapeutic management in ovarian cancer patients leading to an upstaging or down-staging when compared to the CT staging. Therefore, this study will prospectively assess the role of VATS in the diagnosis and management of supradiaphragmatic disease as well as evaluate the impact of VATS findings on the decision of surgical management in patients with advanced ovarian cancer FIGO (The International Federation of Gynecology and Obstetrics) stage III/IV.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
68

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2023

Completed
9 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2023

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 3, 2023

Completed
Last Updated

May 3, 2023

Status Verified

November 1, 2022

Enrollment Period

1.7 years

First QC Date

April 21, 2023

Last Update Submit

April 21, 2023

Conditions

Keywords

ovarian cancer stage III, IV; VATS, CT staging

Outcome Measures

Primary Outcomes (1)

  • Prediction of intrathoracic disease using chest-CT results compared to the standard reference results using VATs

    Comparison between the Chest-CT results in preoperative evaluation of supra-diaphragmatic disease will be compared to the intra-operative VATS evaluation results to evaluate the role of the VATS in those patients

    3 weekS

Secondary Outcomes (1)

  • The rate of change in the treatment plan according to VATs results

    1 week

Study Arms (2)

Group A: Patients who will get neoadjuvant chemotherapy based on VATS finding.

Patients will be considered to receive neoadjuvant chemotherapy if there is residual intrathoracic disease

Procedure: VIDEO-ASSISTED THORACOSCOPIC SURGERY

Group B: Patients who will proceed into debulking surgery based on VATS finding.

Patients will be considered to be eligible for complete debulking, if VATS showed no intrathoracic tumor or if VATS achieves complete removal of tumor nodules through intraoperative frozen section histopathological examination.

Procedure: VIDEO-ASSISTED THORACOSCOPIC SURGERY

Interventions

A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.

Also known as: VATS
Group A: Patients who will get neoadjuvant chemotherapy based on VATS finding.Group B: Patients who will proceed into debulking surgery based on VATS finding.

Eligibility Criteria

Age20 Years - 80 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with advanced ovarian cancer at gyneoncology department will be enrolled

You may qualify if:

  • FIGO stage III/IV ovarian cancer with or without pleural effusion

You may not qualify if:

  • Previously treated ovarian disease.
  • Patient unfit for single lung ventilation.
  • Patients with previous lung surgery.
  • Patients with possible intrapleural adhesions.
  • Patients who had pulmonary resection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alexandria University

Alexandria, 21131, Egypt

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

Thoracic Surgery, Video-Assisted

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Intervention Hierarchy (Ancestors)

ThoracoscopyEndoscopyDiagnostic Techniques, SurgicalDiagnostic Techniques and ProceduresDiagnosisVideo-Assisted SurgeryMinimally Invasive Surgical ProceduresSurgical Procedures, OperativeThoracic Surgical Procedures

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2023

First Posted

May 3, 2023

Study Start

June 1, 2021

Primary Completion

January 30, 2023

Study Completion

April 30, 2023

Last Updated

May 3, 2023

Record last verified: 2022-11

Locations